Animal experiments reveal apigenin reduces LOX-1 and enhances Bcl-2/Bax ratio in atherosclerotic rats, suggesting potential therapeutic effects.
Recently, Apigenin has been widely studied for its anti-atherosclerosis properties, but its mechanism remains to be further elucidated.This study aims to evaluate the expression of LOX-1, Bcl-2 and Bax in apigenin-treated atherosclerotic rats and to explore whether they affect the expression of apoptotic genes.We analyzed the relationship between these three genes and atherosclerosis based on bioinformatics methods and conducted animal experiments on them.We used a fully automatic analyzer to analyze blood lipid levels and found that apigenin has a good effect on lowering blood lipids. Western Blot was used to detect LOX-1 protein, and RT-qPCR was used to detect Bcl-2 and Bax mRNA.The fruit showed that apigenin treatment reduced LOX-1 gene expression while increasing the Bcl-2/Bax ratio. These studies provide an experimental basis for the development of apigenin as a new drug for the treatment of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: